News and Announcements
Folkestone Enters Agreement to Acquire Asset at Sydney Olympic Park
- Published July 27, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Folkestone’s (ASX:FLK) real estate funds management, has recently announced today the Folkestone SOP Opportunity Fund has entered agreement to acquire 11 Murray Rose Avenue, Sydney Olympic Park.
KEY TAKEAWAYS:
- 6-level commercial building, being built by FDC Construction & Fitout (NSW).
- Completion is forecast to occur in February 2018.
- Under the terms of the deal, the Fund has entered into an assignment agreement with the
Vendor, SOP 8D Pty Ltd (an entity associated with FDC) to purchase the interest in the “tobe-created” Asset and “to be granted” 99 year lease of the land.
“We are delighted to have secured 11 Murray Rose Avenue which is our second asset in the Sydney Olympic Park office precinct, following the acquisition of 7 Murray Rose Avenue in 2012 by another Folkestone fund. Sydney Olympic Park is now a thriving centre for business, sport, entertainment, tourism and residential use, which is enhanced by the area’s strategic position within Sydney” said Folkestone’s Managing Director, Mr Greg Paramor.
Folkestone has received commitments from high net worth investors and family offices to invest in the Fund for $24.7 million, being the full amount to be raised by Fund.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
